Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2013-10-21

FDA Approved: ZYPREXA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for ZYPREXA (olanzapine) from Eli Lilly and Company, resulting in labeling changes for the medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zyprexa (olanzapine)

Snippet

SUPPL AP for ZYPREXA (OLANZAPINE)